Following PE Pact, Invitrogen Plans to Grow Presence in Cell-Analysis Market | GenomeWeb

After announcing last week a co-marketing pact with PerkinElmer in the cell analysis field, Invitrogen CEO Greg Lucier told attendees of the UBS Global Life Sciences conference in New York this week that they should expect the company to make further moves to build its presence in that market.

For PerkinElmer, the deal could help it gain better overall name recognition in cell-based screening, which could help its LumiLux platform gain market penetration more rapidly.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.